

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 54515

Manuscript Type: ORIGINAL ARTICLE

Retrospective Cohort Study

Vedolizumab for Ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

Samba Siva Reddy Pulusu¹, Ashish Srinivasan², Krupa Krishnaprasad³, Daniel Cheng⁴, Jakob Begun⁴, Charlotte Keung⁵, Daniel Van Langenberg⁵, Lena Thin⁶, Tamara Mogilevski⁷, Peter De Cruz⁷, Graham Radford-Smith³, Emma Flanagan⁸, Sally Bell⁸, Soleiman Kashkooli⁹, Miles Sparrow¹⁰, Simon Ghaly¹¹, Peter Bampton¹², Elise Sawyer¹³, Susan Connor¹³, Quart-Ul-Ain Rizvi¹⁴, Jane M Andrews¹⁴, Gillian Mahy¹⁵, Paola Chivers¹⁶, Simon Travis², Ian Craig Laurence¹⁷

Match Overview

1	Internet 59 words crawled on 08-Apr-2019 academic.oup.com	1%
2	Crossref 59 words "Inflammatory Bowel Disease Clinical", <i>Journal of Gastroenterology and Hepatology</i> , 2017	1%



ALL

IMAGES

VIDEOS

26,800 Results

Any time ▾

Effectiveness and safety of vedolizumab in inflammatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049246>

Jan 07, 2020 · However, there is a paucity of data exploring the **outcomes** of **vedolizumab** in this group. Our objective was to determine the **clinical effectiveness and safety** of **vedolizumab** in older IBD patients within a **real-world multicenter UK cohort**.

Author: Hajir Ibraheim, Hajir Ibraheim, Mark ... **Publish Year:** 2020

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative ...

https://academic.oup.com/ecco-jcc/article/12/supplement_1/S395/4807936 ▾

Jan 16, 2018 · AbstractBackground. In GEMINI 1, UC response to **vedolizumab** (VDZ) was 47% at Week 6 and 42% by Week 52. Our aim was to assess **real-life outcomes** for VDZ in UC.

Author: S S R Pulusu, A Srinivasan, K Krishn... **Publish Year:** 2018

Vedolizumab in IBD—Lessons From Real-world Experience; A ...

<https://academic.oup.com/ecco-jcc/article/12/2/245/4565692> ▾

Oct 25, 2017 · **Vedolizumab** [VDZ] is an anti-integrin monoclonal antibody effective in **ulcerative colitis** [UC] and **Crohn's disease** [CD]. Several **real-world experience** [RWE] studies with **VDZ** have been published to date. The aim of this systematic review was to summarise the available **real-life** experience with **VDZ**.

Cited by: 63 **Author:** Tal Engel, Bella Ungar, Diana E Yung, Sh...

Publish Year: 2018

Vedolizumab for the treatment of ulcerative colitis ...

https://www.researchgate.net/publication/284277871_Vedolizumab_for_the_treatment_of...

Vedolizumab (VDZ) demonstrated efficacy in **Crohn's disease** (CD) and **ulcerative colitis** (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of **VDZ** at week 14 in inflammatory **bowel disease** in a **multicenter** cohort of patients.



Vedolizumab for ulcerative colitis: Real world outcomes from a multicent



Sign in

ALL IMAGES VIDEOS

30,200 Results Any time

Vedolizumab for Ulcerative Colitis: Treatment Outcomes ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445254>

In this large **real-world cohort** we observed that VDZ was well tolerated and effective in achieving key clinical **outcomes**. INTRODUCTION. **Ulcerative colitis** (UC) is a chronic inflammatory disorder of the colon, characterized by bloody diarrhea, urgency, and abdominal pain. ... a prospective **multicenter observational** study.

Cited by: 34 **Author:** Neeraj Narula, Neeraj Narula, Farhad Pe...
Publish Year: 2018

Search Tools

Turn off Hover Translation (关闭取词)

Real-world Effectiveness and Safety of Vedolizumab for the ...

<https://academic.oup.com/ecco-jcc/article/13/9/1111/5320521>

Feb 14, 2019 · Vedolizumab is a human monoclonal antibody that targets a4b7 integrin and blocks lymphocyte trafficking to the gut via the MADCAM pathway. 6 Following the phase 3 GEMINI trials, that demonstrated **efficacy in induction and maintenance of clinical remission** in both ulcerative colitis [UC] and **Crohn's disease** [CD], vedolizumab was approved as the first gut-selective biologic for the ...

Cited by: 6 **Author:** N Plevris, C S Chuah, R M Allen, I D Arn...
Publish Year: 2019

D314 Real world effectiveness of vedolizumab in ulcerative colitis

30,400 Results Any time ▾

[Vedolizumab for Ulcerative Colitis: Treatment Outcomes ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445254>

In this large **real-world cohort** we observed that VDZ was well tolerated and effective in achieving key clinical **outcomes**. INTRODUCTION. **Ulcerative colitis** (UC) is a chronic inflammatory disorder of the colon, characterized by bloody diarrhea, urgency, and abdominal pain. ... a prospective **multicenter observational** study.

Cited by: 34 **Author:** Neeraj Narula, Neeraj Narula, Farhad Pe...

Publish Year: 2018

[Real-world Effectiveness and Safety of Vedolizumab for the ...](#)

<https://academic.oup.com/ecco-jcc/article/13/9/1111/5320521>

Feb 14, 2019 · Vedolizumab is a human monoclonal antibody that targets α4β7 integrin and blocks lymphocyte trafficking to the gut via the MADCAM pathway. 6 Following the phase 3 GEMINI trials, that demonstrated **efficacy in induction and maintenance of clinical remission** in both ulcerative colitis [UC] and **Crohn's disease** [CD], vedolizumab was approved as the first gut-selective biologic for the ...

Cited by: 7 **Author:** N Plevris, C S Chuah, R M Allen, I D Arno...

Publish Year: 2019

[Comparison of Real-World Treatment Outcomes With ...](#)

<https://academic.oup.com/crohnscolitis360/article/1/2/otz022/5545355>

Aug 09, 2019 · The VICTORY consortium—which studied the largest cohort of patients with IBD treated with vedolizumab in a real-world clinical setting—reported a reduction in vedolizumab effectiveness when used after a TNFα antagonist. 44, 45 A German real-world study found that vedolizumab was **significantly more effective at inducing clinical remission in anti-TNFα-naïve patients than in patients with UC who previously received anti-TNFα therapy...**

Cited by: 1 **Author:** Haridarshan Patel, Dominick Latremouille...

Publish Year: 2019

[Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve ...](#)

<https://pubmed.ncbi.nlm.nih.gov/29788318>

Background: **Vedolizumab** (VDZ) is effective for treatment of **ulcerative colitis** (UC) and Crohn's disease (CD). In GEMINI trials, anti-tumor necrosis factor (anti-TNF)-naïve patients had a superior